NCT06948084View on ClinicalTrials.gov

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo urine and blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Carfilzomib

Given IV

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

DRUG

Daratumumab and Recombinant Human Hyaluronidase

Given SC

DRUG

Dexamethasone

Given PO or IV

PROCEDURE

FDG-Positron Emission Tomography

Undergo FDG PET/CT

DRUG

Pomalidomide

Given PO

DRUG

Teclistamab

Given SC

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH